دورية أكاديمية

Prevalence of Macroprolactinemia in Patients with Hyperprolactinemia Using Roche Elecsys Platform in a Large Tertiary Referral Center in UAE

التفاصيل البيبلوغرافية
العنوان: Prevalence of Macroprolactinemia in Patients with Hyperprolactinemia Using Roche Elecsys Platform in a Large Tertiary Referral Center in UAE
المؤلفون: Abdulla Al Nuaimi, Raya Almazrouei, Yusra Othman, Salem Beshyah, Khaled M. Aldahmani
المصدر: Dubai Diabetes and Endocrinology Journal, Pp 1-5 (2021)
بيانات النشر: Karger Publishers, 2021.
سنة النشر: 2021
المجموعة: LCC:Diseases of the endocrine glands. Clinical endocrinology
مصطلحات موضوعية: hyperprolactinemia, macroprolactin, pituitary, Diseases of the endocrine glands. Clinical endocrinology, RC648-665
الوصف: Objectives: Macroprolactin (macroPRL) excess is an important cause of hyperprolactinemia. Several prolactin assays have high reactivity to macroPRL. However, macroPRL screening is not routinely performed in many labs. This study aimed to evaluate the prevalence of macroprolactinemia (MP) in patients with elevated prolactin using the Roche Elecsys assay in a large tertiary center in UAE. Materials and Methods: Consecutive samples of patients with elevated prolactin presenting to Tawam Hospital from June to August 2018 were evaluated for MP. Polyethylene glycol (PEG) was used to precipitate macroPRL. Monomeric prolactin recovery cutoff ≤50% was used to determine the prevalence of MP. Results: A total of 180 patients with elevated prolactin were included in the study with a mean age of 33.1 ± 11.9 years. The majority were women (87.2%), and about 77.8% were newly diagnosed patients with hyperprolactinemia. The main indications for prolactin testing were menstrual irregularity (n = 121), infertility (n = 11), galactorrhea (n = 11), and sellar masses (n = 12). MP was present in 8.3% of the patients. The median (IQR) of total prolactin level was 740.5 (579–1,085) IU/m before PEG precipitation and was not significantly different between MP and true hyperprolactinemia cases. Three patients with MP had pituitary MRI evaluation, which was normal. Eight patients with MP were treated with cabergoline. Conclusion: One in 12 patients with hyperprolactinemia had MP on the Roche Elecsys assay defined as the cutoff recovery of ≤50% post-PEG precipitation. Physicians should be aware of the prolactin assay used in their labs, and we recommend routine macroPRL assessment in mild hyperprolactinemia samples in labs using the Roche Elecsys platform.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2673-1797
2673-1738
العلاقة: https://www.karger.com/Article/FullText/519094Test; https://doaj.org/toc/2673-1797Test; https://doaj.org/toc/2673-1738Test
DOI: 10.1159/000519094
الوصول الحر: https://doaj.org/article/95ce0acd1b564f3fba92a5e860cd035cTest
رقم الانضمام: edsdoj.95ce0acd1b564f3fba92a5e860cd035c
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:26731797
26731738
DOI:10.1159/000519094